Erasca, Inc. (ERAS)
Health Care ยท Pharmaceutical Preparations
Erasca, Inc. (ERAS) is listed on Nasdaq, where its shares have traded since July 16, 2021. SentiSense covers Erasca, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations. Jonathan E. Lim is its chief executive officer. The company reports 103 employees, and its corporate website is www.erasca.com.
About Erasca, Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
Latest reported results
Erasca, Inc. reported revenue of $0.00 for Q2 FY2026.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 247 institutions reported holding ERAS, with 280.0 million shares worth $5.1 billion in aggregate. The largest reported holders were T. Rowe Price, Frazier Life Sciences Management and BlackRock. Of the 5 largest reported holders, all 5 added shares during the quarter.
More on ERAS
- ERAS sentiment: whether news and social coverage of Erasca, Inc. leans bullish or bearish, and the stories driving it.
- ERAS ownership: all 247 reporting institutions, plus insider and congressional trades.
- ERAS financials: revenue, net income, operating margin and free cash flow through Q2 FY2026.
SentiSense also tracks daily options readings for Erasca, Inc.: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does Erasca, Inc. do?
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.
What sector is ERAS in?
SentiSense classifies Erasca, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.
Where does ERAS stock trade?
Erasca, Inc. (ERAS) is listed on Nasdaq, where its shares have traded since July 16, 2021.
Who is the CEO of Erasca, Inc.?
Jonathan E. Lim is the chief executive officer of Erasca, Inc..